Research Support

RP180178

 Sherry (PI)
Cancer Prevention and Research Institute of Texas (CPRIT)
Title: Imaging glucose stimulated zinc secretion (GSZS) from the prostate by MRI
The goal of this project is to evaluate the use of a zinc-sensitive MRI contrast agent for early detection of prostate cancer in rodent and small animal models of disease.

R01 DK095416-06

 Sherry (PI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Title: Imaging beta cell function in vivo with a zinc-responsive MRI contrast agent/strong>
The goal is to use a low-affinity Zn2+-sensitive MRI agent to detect early responding islets in the mouse pancreas during phase I insulin secretion and to monitor phase I insulin secretion in diabetic models.

P41 EB015908-29

Malloy, Craig R. (PI)
National Center for In Vivo Metabolism
The goal of this project is to develop hyperpolarized agents for imaging glucose production and other pathways, tissue pH, and to develop methods to polarize pyruvate using para-hydrogen.
Role: Co-PI of Project 1

R01 CA115531-11

 Sherry (PI)
National Cancer Institute (NCI)
PARACEST Agents for Molecular Imaging of Cancer by MRI/strong>
The major goal is to develop paramagnetic chemical exchange saturation transfer imaging agents for imaging tissue pH, hypoxia, and other biomarkers.

AT-584

 Sherry (PI)
Robert A. Welch Foundation
Title: Shift reagents for MRI detection of specific metabolites
The purpose of this chemistry grant is to develop newer types of paramagnetic NMR shift reagents for CEST imaging applications.

Past

R01 HL034557 followed by a 10-year R37 grant
R37 HL034557

 Sherry (PI)
National Heart, Lung and Blood Institute (NHLBI)
Title: Metabolism in the Heart by NMR
The principle goal outlined is to develop hyperpolarized 13C techniques to quantitatively measure flux through specific enzyme catalyzed steps in perfused hearts, livers and cancer cells.

RP150456

 Malloy, Craig R. (PI)
TAMU–UT Southwestern Partnership for Breast Imaging and Spectroscopy
Title: Metabolism in the Heart by NMR
To develop 1H and 13C breast imaging at 7 Tesla.

5 R37 HL34557

 Sherry (PI)

National Institute of Health MERIT Award$250,000 annual direct cost
Title: Metabolism in the Heart by NMR
The major goal of this project is to develop hyperpolarized 13C techniques to quantitatively measure flux through specific enzyme catalyzed steps in perfused hearts, livers and cancer cells. 2.40 calendar

2 R01 CA115531

Sherry (PI)

National Institute of Health    $168,539 annual direct cost
Title: PARACEST Agents for Molecular Imaging of Cancer by MRI
The major goal is to develop applications of paramagnetic chemical exchange saturation transfer imaging agents when bound to macromolecules and as small molecule sensors of hypoxia. 1.20 calendar

5 P41 RR02584

Malloy (PI)

National Institute of Health   $151,327 annual direct cost
Title: Southwestern NMR Center for In Vivo Metabolism – Project 1The goal of this project is to develop CEST imaging techniques to image liver glycogen in vivo, to map tissue pH, and to image the distribution of extracellular glucose in tissues in vivo. 0.72 calendar

RP101243-C01

 Sherry (PI)

 CPRIT            $29,338 annual direct cost
Title: Novel MRI and MRS Methods for Imaging Cancer Metabolism: C01
The major goal is the development of biomarkers in tumors to study metabolism, MRI and Hypersense substrates.1.20 calendar

AT-584

Sherry (PI)

 
The Robert A. Welch Foundation (UTD)      $70,000 annual direct cost
Title: Lanthanide-based CEST Agents for Metabolic ImagingThe major goal is to synthesize a series of new DOTA-tetraamide ligands with variable steric strain, charges, and redox properties and examine the CEST properties of the resulting lanthanide complexes.0.40 calendar

1R01 DK095416-01A1

Sherry  (PI)
National Institute of Health  $250,000 annual direct cost
Title: Imaging Beta Cell Function in Vivo with Zinc Responsive MRI Contrast Agent
The goal is to determine the general utility of a novel Zn2+ sensor molecule, GdDOTA-diBPEN, MRI agent for imaging Beta-cell function in anticipation of translating this technology to clinical imaging.1.20 calendar

2 P01 DK058398-11A1

 Sherry (PI)
National Institute of Health/Duke University  $100,000 annual direct cost
Title: Development of Novel Therapies for NIDDIM: Core A
The goal is to provide NMR and tracer core support for the 4 projects of the PO1 grant.0.60 calendar

2 P01 DK058398-11A1

 Malloy (PI)
National Institute of Health/Duke University  $294,209 annual direct cost
Title: Development of Novel Therapies for NIDDIM: Project 40.48 calendar

PC110174

  Sherry/Khemtong (PI)
US Department of Defense   $75,000 annual direct cost
Title: Extracellular pH Imaging of Prostate Tumors by Hyperpolarized 15N MRI
The major goal of this award is to explore 15N-enrihed compounds for pH imaging of prostate tumors by hyperpolarized MRI.0.00 calendar

PC110175

Sherry/Khemtong (PI)
US Department of Defense   $75,000 annual direct cost
Title: Hyperpolarized 15N Magnetic Resonance Imaging of Tumor Hypoxia in Prostrate Cancer
This Idea Development award aims to establish hyperpolarized agents for functional imaging of tumor hypoxia in prostate cancer by 15N-magnetic resonance spectroscopic imaging.0.00 calendar

Innovation Award

Sherry/Anderson (PI)
American Diabetes Association        $47,643 annual direct cost
Title: In Vivo Quantification of Beta Cell Function with MRI Using Zinc Responsive Contrast Agents
To establish the utility of a novel MRI contrast agent that senses beta cell function by testing it’s sensitivity to changes in pancreas function in a pig model of type 1 diabetes and subsequent beta cell implantation.0.36 calendar

Mentor-Based Predoc Fellowship

Sherry/Anderson (PI)
American Diabetes Association $42,910 annual direct cost
Title: In Vivo Imaging of Beta cell Function with Zinc responsive MRI Contrast Agents
To support a postdoc who will test a novel MRI contrast agent sensitive to pancreatic function by researching its effectiveness and then use the agent as a metric for competing beta cell implantation techniques.0.36 calendar

37-2011-21

Li (PI)
Juvenile Diabetes Research Foundation $227,273 annual direct cost
Title: Measuring Beta Cell Function in Human Islets by MRI
The major goal is to label human islets with responsive MRI agents for detecting zinc and proton release during insulin secretion.0.60 calendar

1 R03 NS081584-01A1

Udugamasooriya (PI)
National Institute of Health $150,000
Title: Direct Identification of Ready–to-Use Peptoid-DOTA Theranostic Systems
The goal is to identify peptoids capable of being generated into a new class of drugs with the potential to impact treatment of multiple types of cancer.0.60 calendar

RO1 EB004582

Lenkinski (PI)
National Institute of Health  NIBIB $207,305
Title: PARACEST Agents:  Optimization for Human MR Imaging 
Major Goal: This is a bioengineering partnership application involving further development of the chemistry of PARACEST agents at UT Dallas, development of optimal pulse sequences for clinical scanners at GE Medical, and imaging of PARACEST agents in large animal models (pigs) at UT Southwestern.1.2 calendar

 

Completed

1 R13 EB015773

Sherry (PI)
National Institutes of Health        $25,000
Title: 2012 Metals in Medicine
This conference grant is to support travel and registration fees for scientists to attend the 2012 Gordon Research Conference on Metals in Medicine.  The conference this year will focus on the development of new metal-based drugs for therapy, imaging, and other clinical applications.0.0 calendar

R01 HL34557

Sherry (PI)
National Institutes of Health
Title: Intermediary Metabolism by 13C NMR 
The major goals of this project are to develop novel 13C and 1H NMR techniques for examining intermediary metabolism in intact tissues and to apply such techniques to significant metabolic issues. Current studies involve the kinetics of 13C labeling of glutamate and other intermediates in isolated rat heart mitochondria and indirect 1H detection of 13C labeling in isolated perfuse mouse hearts.

AT-584

Sherry (PI)
The Robert A. Welch Foundation
Title: Lanthanide-based CEST Agents for Molecular Imaging
The major goals of this project are to synthesize a series of new DOTA-tetraamide ligands with variable steric strain, charges, and redox properties and examine the CEST properties of the resulting lanthanide complexes.

RO1 CA115531

Sherry (PI)
National Institutes of Health
Title: PARACEST Agents for Molecular Imaging of Cancer
The major goals of this project are to develop applications of paramagnetic chemical exchange saturation transfer imaging agents when bound to antibody surfaces and as small molecule sensors of hypoxia.

P01 DK058398

Newgard (PI)
National Institutes of Health (renewal – this application)
Title: Development of Novel Therapies for NIDDM
This is a renewal application for a project grant to continue studies of novel targets and imaging agents for imaging pancreatic beta cell function by MRI and PET. Dr. Christopher Newgard of Duke will become the PI of this program project grant involving several scientists at UTSW and at Duke University.

P41 RR02584

Malloy (PI)
National Institute of Health Research Resources grant (renewal application)
Title: Metabolic Imaging Agents
The major goals of this project are to develop CEST imaging techniques for determining liver glycogen in animal models, apply glucose sensitive PARACEST agents to image the distribution of glucose in tissues in vivo and to develop new agents for mapping of tissue pH by MRI.

U24 DK-59632

Malloy (PI)
National Institutes of Health
Title: Metabolic Phenotyping Center for Mouse Models of Diabetes
This project is one element of a national consortium involving three other centers with the shared goal of refining methods for metabolic studies in mice and in providing those methods to the research community.

RO1 EB004582-01

Lenkinski (PI)
National Institutes of Health
PARACEST Agents: Optimization for Human MR Imaging This is a bioengineering partnership application involving further development of the chemistry of PARACEST agents at UT Dallas, development of optimal pulse sequences for clinical scanners at GE Medical, and imaging of PARACEST agents in large animal models (pigs) at the Beth Israel Deaconess Medical Center in Boston, MA.